Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Thrush Clear all

Conditions: Candidiasis
Interventions: Caspofungin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: Oteseconazole (VT-1161) 150mg capsule, Fluconazole 150mg capsule, Placebo; Drug
Lead sponsor: Mycovia Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 33
States / cities: Tucson, Arizona • Encino, California • Los Angeles, California + 30 more

Conditions: Candidiasis
Interventions: Fluconazole Loading Dose, Fluconazole Loading Dose & High Dose; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: 48 Hours to 2 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Bacterial Infections, Bacterial Infections and Mycoses, Infections, Vaginitis, Vaginal Diseases, Genital Diseases, Female, Female Urogenital Diseases, Urogenital Disease, Candidiasis, Mycoses, Vulvovaginitis, Vulvar Diseases, Vaginosis, Bacterial
Interventions: Nanopath Vaginitis Assay, BD Max™ Vaginal Panel, Cepheid Xpert® Xpress MVP, Hologic Aptima® BV Assay, Yeast Culture; Diagnostic Test
Lead sponsor: Nanopath, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: North Miami, Florida • New Orleans, Louisiana

Conditions: Candida Infection, Premature Infant
Interventions: Medium-Chain Triglyceride (MCT) Oil; Drug
Lead sponsor: Joseph Bliss; Other
Eligibility: Up to 6 Months
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Acquired Immunodeficiency Syndrome, Candidiasis, Oral Candidiasis
Interventions: fluconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bacterial Vaginosis, Vulvovaginal Candidiasis
Interventions: TOL-463; Drug
Lead sponsor: Toltec Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Birmingham, Alabama • Seattle, Washington

Conditions: Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions: Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more

Conditions: Candidiasis, Candidiasis, Esophageal, HIV Infections
Interventions: Fluconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 16
States / cities: San Francisco, California • Denver, Colorado • Wilmington, Delaware + 11 more

Conditions: Staphylococcal Infections, Candidiasis
Interventions: NDV-3 investigational vaccine; Biological
Lead sponsor: NovaDigm Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Candidiasis, Esophageal, HIV Infections
Interventions: Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Mycoses
Interventions: Voriconazole; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Vaginal Discharge, Trichomonas, Candidiasis, Vaginosis, Bacterial, Vaginitis
Interventions: vaginal swab; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Bacterial Vaginosis, Vulvovaginal Candidiasis
Interventions: Phexxi; Drug
Lead sponsor: Queen's Medical Center; Other
Eligibility: 18 Years to 54 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Oral Candidiasis
Interventions: PAC113; Drug
Lead sponsor: Pacgen Biopharmaceuticals Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Huntersville, North Carolina

Conditions: Candidiasis
Interventions: Anidulafungin, VER002; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: King of Prussia, Pennsylvania

Conditions: Aspergillosis, Candidiasis, Fungemia, Mycoses
Interventions: FK463, Fluconazole; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Candidiasis, Mycoses, HIV Infections
Interventions: Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Groton, Connecticut

Conditions: Bacterial Vaginosis, Candidiasis, Trichomoniasis
Interventions: Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate), Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Itraconazole; Drug
Lead sponsor: Janssen, LP; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Berkeley, California + 13 more

Conditions: Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis
Interventions: Micafungin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 7
States / cities: Los Angeles, California • Orange, California • Kansas City, Missouri + 4 more

Conditions: Candida Systemic, Candida Albicans Infection, Candida Infection
Interventions: CanXida Remove (Formula RMV), Placebo; Dietary Supplement · Other
Lead sponsor: CanXida; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Candidiasis, Mycoses, HIV Infections
Interventions: Clotrimazole, Fluconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 25
States / cities: Palo Alto, California • San Diego, California • San Francisco, California + 18 more

Conditions: Candidiasis, Vulvovaginal, Mycoses, Yeast Infection, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions: CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%), CD101 External ointment (1%), Fluconazole; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older · Female only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more

Search by objective public record fields.

Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units

Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections

Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers

Large Algorithm Setting and Validation Study

Effect of Medium Chain Triglyceride Intake on Colonization of Preterm Infants With Candida

Fluconazole Prophylaxis of Thrush in AIDS

TOL-463 Phase 2 Study for Vaginitis

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women

Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida

A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

Voriconazole to Treat Fungal Infections

Validity of Patient-Collected Wet Mounts

Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome

Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis

The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients

Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy

Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women

An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

Clinical Study to Evaluate the Efficacy of an Anti-Fungal Supplement

Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)

RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections